Evolocumab in patients with homozygous familial hypercholesterolemia in India

Sandeep Bansal,Andrea Ruzza,Jps Sawhney, Govind Kulkarni, Shammana Iyengar,Vimal Mehta,Andrew Hamer,You Wu,Frederick J Raal

Journal of Clinical Lipidology（2021）

引用 8|浏览15

暂无评分

摘要

•Evolocumab was well tolerated in patients aged ≥12 and <80 years with HoFH in India.•Evolocumab was generally associated with reduction in LDL-C.•Lipid-lowering efficacy of evolocumab varied by age and baseline LDL-C.•Pharmacogenetic testing of HoFH patients may identify responders to evolocumab.

查看译文

关键词

Low-density lipoprotein cholesterol,PCSK9,Evolocumab,Homozygous familial hypercholesterolemia,Familial hypercholesterolemia,Apolipoprotein B,Lipoproteins,Lipoprotein(a)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要